CEPI (Coalition for Epidemic Preparedness Innovations)
William Dowling has extensive experience in infectious disease research and vaccine development, currently serving as the Head of the Preclinical Development Group and Non-Clinical Vaccine Development Leader at the Coalition for Epidemic Preparedness Innovations (CEPI) since January 2020. Prior to this role, William held various positions at the National Institute of Allergy and Infectious Diseases (NIAID) from March 2012 to January 2020, including Chief of the Research Resources Section and Program Officer. William also worked as a Senior and S&T Manager at the Defense Threat Reduction Agency from October 2006 to March 2012, and briefly as a Senior Principal Scientist at Anteon in 2006. Earlier experience includes a role as a Microbiologist with the US Army from 1999 to 2006 and as a Research Scientist at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) from June 2003 to December 2005. William holds a PhD in Molecular Microbiology from Stony Brook University and a Bachelor's degree in Biology from Lafayette College.
This person is not in any offices
CEPI (Coalition for Epidemic Preparedness Innovations)
2 followers
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net